Industry Symposia
Symposia Information
Symposia A
Date: Wednesday, 7 May 2025
Time: 11.00 – 12.00
Room: Europaea
The Unbearable Itch; Unveiling the Complexities of Prurigo Nodularis
Chronic prurigo, or prurigo nodularis (PN), is one of dermatology’s most challenging conditions, characterized by persistent itch and nodular lesions that severely impact patients’ lives. This session explores PN’s medical history, epidemiology and pathophysiology, including changes in skin architecture, key signaling molecules such as IL-31, and receptor complexes driving chronic itch. It also addresses the profound sensory, mental, and social burdens of PN, including its disruption of sleep and quality of life. Finally, treatment options will be reviewed, providing insights to enhance patient care by integrating the latest research with clinical expertise.
Speakers:
MD, PhD, Chief Physician, Associate Professor
Jesper Elberling
Symposia B
Date: Wednesday, 7 May 2025
Time: 12.15 – 13.15, Lunch
Room: Europaea
Managing Atopic Dermatitis: New Treatments & Clinical Insights - an interactive session on clinical cases
Moderator introduces the overall topic 10 minutes.
Each panelist introduces a topic 5 min. and then discuss a clinical case 8 min.
Round off 11 min.
Each panelist presents a case with data included followed by an interactive case discussion where cases are presented bit by bit, interrupted by a) interactive polls in the audience, visual on a central screen b) panel discussions of the possible/suggested solutions to specific challenges. Topics of the cases could e.g. be: 1) Body weight & Skin of color (SE), 2) head and neck, conjunctivitis, 3) immediate onset of action/long-term control.
Speakers:
German speaker and moderator: Stephan Weidinger
DK speaker: Christian Vestergaard
SE speaker: Maria Bradley (to be confirmed)
NO speaker: Teresa Berents, Eva Rehbinder, or Astrid Lossius (to be confirmed)
Symposia C
Date: Thursday, 8 May 2025
Time: 12.15 – 13.15, Lunch
Room: Europaea
Cornucopia of Real World Evidence in AD&PN in Nordics – Clinicians toolbox to uncover what do we know of longterm treatment in AD & PN from real life registries
We are looking for establishing engaging session to cover the essentials of available new real world evidence in a variety of acknowledged, high quality registries in Nordics in AD & PN from the perspective of what new do we know now and how this information can benefit in everyday work the decision making with patients. Panel of experts will reveal their insights, findings and discuss the opportunities of this kind of information.
Speakers:
We have no confirmed speakers yet. Planning to build a discussion panel with experts from Finland, Sweden, Norway and Denmark that have conducted work with AD & PN registries and for example published recently.
Symposia D
Date: Thursday, 8 May 2025
Time: 15.30 – 16.30, Afternoon
Room: Europaea
Nordic European Cutaneous Oncodermatology Management (NECOM) project tools to prevent and treat cancer therapy-related cutaneous adverse events
The Nordic European Cutaneous Oncodermatology Management (NECOM) project develops tools to prevent and treat cancer therapy-related cutaneous adverse events (cAEs). This project aims to develop evidence-based algorithms that aim to improve patient and survivor comfort during and after treatment, reduce and treat cAEs, and promote the healing of affected skin areas by using prescription medication and skincare.
The target audience is not only dermatologists and oncologists but also a broad range of HCPs, including nurses, physician assistants, GPs, and pharmacists.
The first 2 NECOM papers presented various cAEs and skincare regimens involving hygiene, moisturization, sun protection, and camouflage products for preventing and managing cAEs. The NECOM 3 practical algorithm focused on preventing and treating acute radiation dermatitis. The NECOM 4 practical algorithm addressed the prevention and management of cutaneous immunotherapy-related adverse events, improving cancer patients’ QoL and outcomes.
The NECOM 5 practical algorithm is intended to prevent and manage cutaneous targeted therapy-related adverse events (TTcAEs), improving cancer patients’ QoL and outcomes. Quality of life is highly important to cancer patients. Integrating skincare into treatment can improve the patient experience and support adherence to cancer treatment. It is important to recommend/select the right skincare products (both active ingredients and vehicle). Patients should be encouraged to adopt a proactive approach to caring for their skin before, during, and continue after cancer-targeted therapy.
Speakers:
Peter Bjerring, MD, Dr.Sci.
Ada Girnita, MD, PhD
Sampsa Kauppi, MD
Andreas Stensvold, MD, PhD